Καταχωρήθηκε: Τρίτη 22 Φεβ 2022
Presenter: Prof. Spyridonidis
Participants: Dr Liga, Dr Tsokanas, Sagiadinou E., Christopoulou A., Panagi Z.

Post-transplant cyclophosphamide (PTCY) is increasingly used for allogeneic peripheral blood stem cell transplantation (allo-PBSCT) from an HLA-matched unrelated donor (MUD) as an alternative to the standard anti-thymocyte globulin (ATG) graft-versus-host disease (GvHD) prophylaxis. Following the demonstration that the use of PBSC
haploidentical grafts results in more GvHD than bone marrow grafts, groups have attempted to reduce GvHD in haploidentical-PBSCT by adding ATG to PTCY. The experience of combined PTCY+ATG in the MUD allo-PBSCT is minimal and whether ATG brings any added value when PTCY is used in this setting is still unclear.

Though addition of ATG does not seem to provide any extra benefit in terms of further GVHD reduction when a PTCY regimen is used, our results indicate that such a dual PTCY+ATG based GVHD prophylaxis is a feasible strategy in MUD allo-PBSCT without detrimental effect on AML control. Future studies should evaluate the optimal dose and timing for the PTCY+ATG combination

Σχετικά Αρχεία



Τηλέφωνα Επικοινωνίας:


Γραμματεία MMMO: 2613 603506 (ασθενείς), 2613 604062 (Γραμματεία Διευθυντή) 
Fax : 2613 604066,
email (για ιατρούς): transplant@upatras.gr,
email (για ασθενείς): mmak@upatras.gr
email (για θέματα κλινικών μελετών) : gcppatras@gmail.com
Μονάδα Μεταμόσχευσης (Νοσηλεία): 2613 603 261
Γραφείο Ιατρών: 2613 604064, 2613 604065,
Εφημερεύων Ιατρός: 2610 999111 (τηλ. κέντρο ΠΓΝΠ)


βρείτε μας στο χάρτη


Login / Sitemap


© Copyright 2015 - 2022 Μονάδα Μεταμόσχευσης Μυελού των Οστών Πάτρας